{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:37:07Z","timestamp":1791423427371,"version":"4.3.3"},"reference-count":124,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijantimicag.2016.04.017","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T16:09:18Z","timestamp":1463501358000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance"],"prefix":"10.1016","volume":"48","author":[{"given":"Spyros","family":"Pournaras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Koumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Spanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Gennimata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanassios","family":"Tsakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijantimicag.2012.09.005","article-title":"The emergence of clinical resistance to tigecycline","volume":"41","author":"Sun","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2016.04.017_bib0015","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1086\/431672","article-title":"Tigecycline: a new glycylcycline for treatment of serious infections","volume":"41","author":"Noskin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0020","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1128\/AAC.48.6.2179-2184.2004","article-title":"Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936)","volume":"48","author":"Hirata","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.43.4.738","article-title":"In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)","volume":"43","author":"Petersen","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0030","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/AAC.49.4.1636-1638.2005","article-title":"Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline","volume":"49","author":"Fluit","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0035","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/jac\/dkq288","article-title":"Zone breakpoints, by the CLSI disc method, for 15\u2009\u00b5g tigecycline discs corresponding to EUCAST MIC breakpoints","volume":"65","author":"Hope","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0040","series-title":"Antimicrobial resistance surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","year":"2014"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.diagmicrobio.2012.12.004","article-title":"Tigecycline: an update","volume":"75","author":"Stein","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0055","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0060","series-title":"Tygacil package insert","author":"Wyeth Pharmaceuticals Inc","year":"2005"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0065","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/AAC.05879-11","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0070","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1128\/JCM.00637-08","article-title":"In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and Etest","volume":"46","author":"Pillar","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0075","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1128\/JCM.02534-10","article-title":"Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest","volume":"49","author":"Lat","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0080","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1128\/JCM.00089-07","article-title":"Validation and reproducibility assessment of tigecycline MIC determinations by Etest","volume":"45","author":"Bolmstrom","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0085","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1128\/JCM.02037-12","article-title":"Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant Gram-negative pathogens","volume":"50","author":"Zarkotou","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0090","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/AAC.01726-09","article-title":"Evaluation of Etest to determine tigecycline MICs for Enterobacter species","volume":"54","author":"Cohen Stuart","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0095","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/JCM.02464-08","article-title":"High concentrations of manganese in Mueller\u2013Hinton agar increase MICs of tigecycline determined by Etest","volume":"47","author":"Fern\u00e1ndez-Mazarrasa","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0100","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1128\/JCM.00119-10","article-title":"Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC","volume":"48","author":"Torrico","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0105","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1128\/JCM.01485-12","article-title":"Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline","volume":"50","author":"Veenemans","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/JCM.00001-14","article-title":"Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method","volume":"52","author":"Marchaim","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0115","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/jac\/dks288","article-title":"In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline","volume":"67","author":"Huang","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/medicina46040033","article-title":"Tigecycline\u2014how powerful is it in the fight against antibiotic-resistant bacteria?","volume":"46","author":"Seputiene","year":"2010","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0125","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/AAC.47.3.972-978.2003","article-title":"Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1","volume":"47","author":"Dean","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0130","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/AAC.49.2.791-793.2005","article-title":"AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.47.2.665-669.2003","article-title":"AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis","volume":"47","author":"Visalli","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0140","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1128\/AAC.45.5.1550-1552.2001","article-title":"Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of Escherichia coli","volume":"45","author":"Webber","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0145","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1128\/JB.184.23.6490-6499.2002","article-title":"Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops","volume":"184","author":"Elkins","year":"2002","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2958.1996.357881.x","article-title":"The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals","volume":"19","author":"Ma","year":"1996","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2958.1995.tb02390.x","article-title":"Genes acrA and acrB encode a stress-induced efflux system of Escherichia coli","volume":"16","author":"Ma","year":"1995","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0160","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.48.7.2518-2523.2004","article-title":"RamA is an alternate activator of the multidrug resistance cascade in Enterobacter aerogenes","volume":"48","author":"Chollet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0165","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1128\/AAC.01085-12","article-title":"Effect of transcriptional activators SoxS, RobA, and RamA on expression of multidrug efflux pump AcrAB\u2013TolC in Enterobacter cloacae","volume":"56","author":"P\u00e9rez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jac\/dkm397","article-title":"MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli","volume":"61","author":"Keeney","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0175","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1046\/j.1365-2958.2003.03952.x","article-title":"Proteolytic degradation of Escherichia coli transcription activators SoxS and MarA as the mechanism for reversing the induction of the superoxide (SoxRS) and multiple antibiotic resistance (Mar) regulons","volume":"51","author":"Griffith","year":"2004","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0180","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/AAC.49.3.1017-1022.2005","article-title":"Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae","volume":"49","author":"Ruzin","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0185","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1128\/AAC.00085-10","article-title":"ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline","volume":"54","author":"Hentschke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0190","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jac\/dkt432","article-title":"RamA, which controls expression of the MDR efflux pump AcrAB\u2013TolC, is regulated by the Lon protease","volume":"69","author":"Ricci","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2011.02.012","article-title":"Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae","volume":"38","author":"Rosenblum","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0200","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1128\/AAC.00456-12","article-title":"Characterization of RarA, a novel AraC family multidrug resistance regulator in Klebsiella pneumoniae","volume":"56","author":"Veleba","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0205","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1128\/AAC.06224-11","article-title":"Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae","volume":"56","author":"Veleba","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0210","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/AAC.41.10.2067","article-title":"Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon","volume":"41","author":"Alekshun","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0215","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1128\/JB.182.12.3467-3474.2000","article-title":"Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA","volume":"182","author":"Barbosa","year":"2000","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0220","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/jac\/dkt263","article-title":"Mechanisms and fitness costs of tigecycline resistance in Escherichia coli","volume":"68","author":"Linkevicius","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0225","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/AAC.05509-11","article-title":"Involvement of the AcrAB\u2013TolC efflux pump in the resistance, fitness, and virulence of Enterobacter cloacae","volume":"56","author":"P\u00e9rez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/dkp475","article-title":"Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY\u2013HasF efflux system also active against ciprofloxacin and cefpirome","volume":"65","author":"Hornsey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0235","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/jac\/dks530","article-title":"Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes","volume":"68","author":"Veleba","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0240","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijantimicag.2010.01.011","article-title":"Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment","volume":"35","author":"Hornsey","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/mdr.2006.9990","article-title":"RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae","volume":"13","author":"Keeney","year":"2007","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0250","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.00591-08","article-title":"Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae","volume":"52","author":"Ruzin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115185","article-title":"First emergence of acrAB and oqxAB mediated tigecycline resistance in clinical isolates of Klebsiella pneumoniae pre-dating the use of tigecycline in a Chinese hospital","volume":"9","author":"Zhong","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0260","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ijantimicag.2014.12.022","article-title":"Genetic characterisation of clinical Klebsiella pneumoniae isolates with reduced susceptibility to tigecycline: role of the global regulator RamA and its local repressor RamR","volume":"45","author":"Wang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0265","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jac\/dks535","article-title":"Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007\u201310) and role of an efflux pump in tigecycline non-susceptibility","volume":"68","author":"Roy","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0270","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jac\/dkp186","article-title":"Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City","volume":"64","author":"Bratu","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0275","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1128\/AAC.01998-12","article-title":"Elucidating the regulon of multidrug resistance regulator RarA in Klebsiella pneumoniae","volume":"57","author":"De Majumdar","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0280","article-title":"Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae","volume":"10","author":"He","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0285","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1128\/AAC.01574-08","article-title":"oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae","volume":"53","author":"Kim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0290","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1128\/AAC.03808-14","article-title":"Mechanisms of tigecycline resistance among Klebsiella pneumoniae clinical isolates","volume":"58","author":"Sheng","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0295","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1128\/AAC.01803-13","article-title":"Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance","volume":"58","author":"Villa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0300","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1128\/AAC.03053-14","article-title":"IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae","volume":"58","author":"Nielsen","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0305","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13099-014-0040-2","article-title":"Genome sequencing and genomic characterization of a tigecycline-resistant Klebsiella pneumoniae strain isolated from the bile samples of a cholangiocarcinoma patient","volume":"6","author":"Zheng","year":"2014","journal-title":"Gut Pathog"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0310","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diagmicrobio.2013.02.009","article-title":"Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)","volume":"76","author":"Sader","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2011.11.023","volume":"34","author":"Bertrand","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2005.05.005","article-title":"Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0325","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diagmicrobio.2009.07.010","article-title":"In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007","volume":"65","author":"Garrison","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0330","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.01114-07","article-title":"Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-\u03b2-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program","volume":"52","author":"Castanheira","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-015-0085-1","article-title":"Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004\u20132013","volume":"14","author":"Hoban","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0340","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10096-008-0629-9","article-title":"In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital","volume":"28","author":"Naesens","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0345","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-0711-11-29","article-title":"Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010","volume":"11","author":"Fernandez-Canigia","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.diagmicrobio.2010.10.020","article-title":"Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005\u20132009)","volume":"69","author":"Sader","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0355","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.clinthera.2008.11.006","article-title":"Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007","volume":"30","author":"Dowzicky","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0360","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diagmicrobio.2010.10.027","article-title":"Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada\u2014results of the CANWARD 2007\u20132009 study","volume":"69","author":"Lagace-Wiens","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0365","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1590\/S1413-86702008000500012","article-title":"Rates of antimicrobial resistance in Latin America (2004\u20132007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics","volume":"12","author":"Rossi","year":"2008","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0370","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.diagmicrobio.2010.12.018","article-title":"In vitro activity of tigecycline against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study","volume":"70","author":"Silva-Sanchez","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0375","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/mdr.2009.0031","article-title":"Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae","volume":"16","author":"Castanheira","year":"2010","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0380","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-0711-12-24","article-title":"Antimicrobial susceptibility among Gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)","volume":"12","author":"Denys","year":"2013","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0385","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/AAC.02684-13","article-title":"Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0390","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijantimicag.2006.10.019","article-title":"Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial","volume":"29","author":"DiPersio","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2016.04.017_bib0395","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0924-8579(08)70024-4","article-title":"Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"32","author":"Lu","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0400","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijantimicag.2008.07.031","article-title":"Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"33","author":"Bouchillon","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0405","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10096-009-0801-x","article-title":"In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001\u20132006","volume":"28","author":"Liu","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0410","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijantimicag.2010.12.003","article-title":"In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents","volume":"37","author":"Hsu","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0415","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1128\/AAC.06053-11","article-title":"Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010","volume":"56","author":"Chen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0420","first-page":"DC1","article-title":"Emergence of Escherichia coli, co-producing NDM-1 and OXA-48 carbapenemases, in urinary isolates, at a tertiary care centre at central India","volume":"8","author":"Khajuria","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0425","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.diagmicrobio.2008.08.011","article-title":"Tigecycline in vitro activity against commonly encountered multidrug-resistant Gram-negative pathogens in a Middle Eastern country","volume":"62","author":"Araj","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0430","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.diagmicrobio.2014.01.017","article-title":"In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007\u20132012","volume":"79","author":"Renteria","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0435","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000339200","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline","volume":"21","author":"Al-Zarouni","year":"2012","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0440","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10096-011-1197-y","article-title":"Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany","volume":"30","author":"Kresken","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0445","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijantimicag.2009.02.003","article-title":"Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004\u20132007)","volume":"34","author":"Norskov-Lauritsen","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0450","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijantimicag.2011.10.010","article-title":"In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004\u20132009)","volume":"39","author":"Andrasevic","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0455","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.patbio.2008.08.006","article-title":"Activity of tigecycline against pathogen bacteria isolated in respiratory infectious disease in Europe. TEST study 2004\u20132007","volume":"57","author":"Rio","year":"2009","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0460","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2009.09.012","article-title":"In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints","volume":"66","author":"Papaparaskevas","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0465","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2013.02.022","article-title":"Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004\u20132010","volume":"41","author":"Balode","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0470","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2047-2994-3-36","article-title":"A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012","volume":"3","author":"Cattoir","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0475","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.patbio.2011.11.008","article-title":"In vitro activity of tigecycline on 760 bacterial strains isolated in the hospital university of Angers\u20142006\u20132009 TEST study","volume":"60","author":"Bris","year":"2012","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0480","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0485","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","article-title":"Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010\u20132013)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0490","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.patbio.2013.01.009","article-title":"Tigecycline: CMI 50\/90 towards 1766 Gram-negative bacilli (3rd generation cephalosporins resistant Enterobacteriaceae), Acinetobacter baumannii and Bacteroides fragilis group, University Hospital\u2013Montpellier, 2008\u20132011","volume":"61","author":"Froment Gomis","year":"2013","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0495","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0500","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/jac\/dkl414","article-title":"Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England","volume":"58","author":"Hope","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0505","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/jac\/dkl514","article-title":"In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp","volume":"59","author":"Woodford","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0510","first-page":"121","article-title":"Re-defining tigecycline therapy","volume":"38","author":"De Rosa","year":"2015","journal-title":"New Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0515","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1128\/JCM.42.6.2701-2706.2004","article-title":"Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey","volume":"42","author":"Hasdemir","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0520","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.46.8.2640-2643.2002","article-title":"The AcrAB\u2013TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes","volume":"46","author":"Pradel","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0525","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/AAC.00715-09","article-title":"Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence","volume":"54","author":"Padilla","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0530","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0535","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/jac\/dkq224","article-title":"Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"65","author":"Geerlings","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0540","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/JCM.01340-07","article-title":"Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"46","author":"Krueger","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0545","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1093\/jac\/dku185","article-title":"Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline","volume":"69","author":"Brust","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0550","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1179\/joc.2007.19.6.753","article-title":"Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection","volume":"19","author":"Cunha","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0555","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1469-0691.2011.03482.x","article-title":"Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient","volume":"18","author":"Rodr\u00edguez-Avial","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0560","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4103\/0255-0857.76535","article-title":"First case of resistance to tigecycline by Klebsiella pneumoniae in a European university hospital","volume":"29","author":"Neonakis","year":"2011","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0565","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4103\/0256-4947.67087","article-title":"Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient","volume":"30","author":"Al-Qadheeb","year":"2010","journal-title":"Ann Saudi Med"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0570","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1128\/AAC.01592-08","article-title":"Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy","volume":"53","author":"Daurel","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0575","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1128\/AAC.00234-12","article-title":"In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Spanu","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0580","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0585","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jinf.2009.02.009","article-title":"Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens","volume":"58","author":"Poulakou","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0590","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s15010-014-0653-x","article-title":"The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients","volume":"42","author":"Papadimitriou-Olivgeris","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0595","series-title":"FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning","author":"US Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0600","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0605","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0610","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cis270","article-title":"Excess deaths associated with tigecycline after approval based on noninferiority trials","volume":"54","author":"Prasad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0615","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","article-title":"All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials","volume":"41","author":"McGovern","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0620","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2016.04.017_bib0625","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijantimicag.2010.10.031","article-title":"Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay","volume":"37","author":"Pournaras","year":"2011","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T19:16:43Z","timestamp":1567883803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916300954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0924857916300954"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}